

Precision Dosing Summary Report

Saarland University

Warning: package 'readr' was built under R version 4.3.3

Warning: package 'knitr' was built under R version 4.3.3

Precision Dosing Summary Report for Voriconazole

for Patient: 2

Date: 30.04.2025
Report version: 0.1

developed by
Simeon Rüdesheim, Dominik Selzer, Helena Loer, Laura Fuhr, Fatima Marok, and Thorsten Lehr
Clinical Pharmacy, Saarland University, Germany

Disclaimer: This application is provided for informational and educational purposes only. It is not intended to be a medical device or a substitute for professional medical advice, diagnosis, or treatment. The use of this app should not be considered as a substitute for consulting with a qualified healthcare professional. Users are advised not to make clinical decisions based solely on the results or information provided by this app. Always seek the advice of a healthcare professional for any medical concerns or questions.

Grant No. 101057639



Funded by
the European Union

1 General Information

This application is driven by physiologically-based pharmacokinetic (PBPK) models and predicts patient-specific pharmacokinetics of Voriconazole taking individual characteristics, such as age, weight, pharmacogenetics and drug-drug interactions into account.

2 Input

2.1 Patient related information

This section provides an overview of the patient demographics and relevant genetic information for pharmacogenes associated with the drug response provided to the system. Based on respective covariates, the PBPK model predicts the pharmacokinetics of Voriconazole.

2.1.1 Patient Demographics

Table 1: Demographic information of patient 2

ID	Age	Weight	Height	Sex	Ethnicity
2	60	40	150	female	asian

2.1.2 Genetics

Table 2: Genetic information of patient 2

Gene	Genotype
CYP2D6	2x*1/2x*2

2.2 Dosing Data

The following table displays the administration schedules of Voriconazole and the perpetrator drugs provided to the system. This dosing schedule is used to calculate individual Voriconazole pharmacokinetics.

Table 3: Dosing information for Voriconazole and perpetrator drugs

Drug	Date	Clock time	Dose [mg]
Cimetidine	2025-04-28	08:00:00	100
Voriconazole	2025-04-28	08:00:00	95
Voriconazole	2025-04-28	18:00:00	95
Cimetidine	2025-04-29	08:00:00	100
Voriconazole	2025-04-29	08:00:00	95
Voriconazole	2025-04-29	18:00:00	95
Cimetidine	2025-04-30	08:00:00	100
Voriconazole	2025-04-30	08:00:00	95
Voriconazole	2025-04-30	18:00:00	95
Cimetidine	2025-05-01	08:00:00	100
Voriconazole	2025-05-01	08:00:00	95
Voriconazole	2025-05-01	18:00:00	95
Cimetidine	2025-05-02	08:00:00	100
Voriconazole	2025-05-02	08:00:00	95
Voriconazole	2025-05-02	18:00:00	95

3 Results

3.1 Dose simulations

The pharmacokinetics of Voriconazole are calculated for different predefined doses. Results are displayed in the following figures and tables.





Table 4: Pharmacokinetic parameters of Voriconazole estimated for different dosing schedules

Dose [mg]	AUC [days * mg/L]	C _{max} [mg/L]	C _{trough} [mg/L]	C _{ss, average} [mg/L]	Steady state
(100-100)	0.51	1.53	0.08	0.51	yes
(150-150)	0.96	2.67	0.20	0.96	yes
(200-200)	1.50	3.67	0.38	1.50	yes
(250-250)	1.95	4.26	0.63	1.95	yes
(300-300)	2.17	4.54	0.73	2.17	yes
(350-350)	2.34	4.77	0.80	2.34	yes
(400-400)	2.48	4.95	0.87	2.48	yes
(50-50)	0.19	0.62	0.02	0.19	yes
(95-95)	0.48	1.42	0.08	0.48	yes

Voriconazole concentration–time profile



— Alternative doses after 2025–05–03 02:01 - - Original doses: (95–95) [mg]



Funded by
the European Union